Loading... (0%)
About liver disease
Genfit is a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions to address high unmet patient needs...
Learn more
NASH: Optimizing therapy for progressive disease April 2016
Watch

Press releases
  • GENFIT is Filing for IND Submission for New Indication of Elafibranor in Primary Biliary Cholangitis (PBC)
    09/27/2016
  • GENFIT: H1 2016 Results: Cash position at end of period at €94M and significant advances in Elafibranor program
    09/26/2016
  • GENFIT: Successful identification of RORγt inverse agonists as candidates for regulatory pre-IND studies
    09/23/2016
  • GENFIT: Significant Milestones Achieved under a New Qualification Program of Proprietary miRNAs and Algorithms for a Non-invasive NASH Diagnostic
    09/20/2016
Events